Dr. Anne Winkler, M.D., Ph.D. – Rheumatology

//Dr. Anne Winkler, M.D., Ph.D. – Rheumatology
Dr. Anne Winkler, M.D., Ph.D. – Rheumatology2019-03-09T07:59:56-05:00
Dr. David McLaren, MD

PSN Rheumatologist: Dr. Anne Winkler, M.D., Ph.D.

Dr. Anne Winkler, M.D., Ph.D, received her medical degree from the University of Missouri-Columbia, where she also completed her residency in Internal Medicine and her Fellowship in Rheumatology. She completed her PhD in Microbiology at the University of Missouri-Columbia as well. She has practiced Rheumatology in the Springfield area since 1989. She has published over 15 papers in the area of Rheumatology, and continues to serve as principle investigator in clinical research trials. Dr. Winkler has won the 417 Magazine Best Doctor in Rheumatology in 2009, 2008, 2006, 2005, 2003 and 2002. She has also served as Governor of the American College of Physicians (ACP). Dr. Winkler was awarded mastership in the ACP in 2008.
PhD: PhD, Microbiology University of Missouri Columbia, Missouri 1985 – 1989 MD: Doctor of Medicine University of Missouri Columbia, Missouri 1977 – 1981 BA: Bachelor of Arts University of Pennsylvania 1971 – 1974 Residency:  Resident, Internal Medicine University of Missouri Columbia, Missouri 1981 – 1984 Fellowship: Fellow, Division of Immunology/Rheumatology University of Missouri Columbia, MO
2007 – Voted Springfield’s Best Rheumatologist 2005 – Voted Springfield’s Best Rheumatologist 2003 – Voted Springfield’s Best Rheumatologist 2003 – Woman of the Year, Springfield Business Journal 2002 – Voted Springfield’s Best Rheumatologist 2002 – Lifetime Member of Who’s Who 1996 – Who’s Who of American Women 1995 – International Who’s Who of Professionals 1994 – Fellow, American College of Physicians 1991 – Who’s Who in Medicine 1987 – 1989 – Arthritis Foundation Postdoctoral Fellow Grant 1986 – Diplomate, Subspecialty – Rheumatology, American Board of Internal Medicine 1984 – Diplomate, American Board of Internal Medicine 1981 – Licensure, State of Missouri 1974 – Phi Beta Kappa 1974 – Magna cum laude, University of Pennsylvania 1972, 1973, 1974 – Academic Distinction, University of Pennsylvania 1971 – National Merit Finalist
  • American Medical Women’s Association, 1980 – present
  • American College of Physicians, 1989 – present
  • Association for the Advancement of Science, 1984 – present
  • American College of Rheumatology, 1989 – present
  • Southwest Regional Arthritis Center at St. John’s Regional Health Center, 1989 – present
  • Missouri Juvenile Arthritis Task Force, 1991 – 1992
  • Missouri Arthritis Advisory Board, 1990 – present
  • St. John’s Medical Research Institute Board, 2007 – present
  • The Summit Preparatory School Board 2004 – present
  • 2007 – present: Member, St. John’s Medical Research Institute Board
  • 2005 – 2007: Leader, Midwest Rheumatology Association, Ozark Branch
  • 2004 – present: Chair, The Summit Preparatory School Board of Trustees
  • 2003 – 2007: Governor, ACP
  • 2002 – 2005: Leader, Women Physicians Group
  • 2002 – 2003: Governor – Elect, ACP
  • 1999 – 2002: Council Member, Missouri ACP
  • 1998 –2000: Chair, Physician Manpower Committee
  • 1998 – present: Medical Editor, Southwest Missouri Regional Arthritis Center Newsletter
  • 1998 – present: Medical Director, Fibromyalgia Support Services, St. John’s Hammons Heart Institute
  • 1996 – present: Activities Committee, Missouri ACP
  • 1994 – present: Medical Advisor, Fibromyalgia Support Group
  • 1993 – 1994: Chair, Department of Medicine Subspecialties
  • 1990 present: Medical Director, Ozark Lupus Group
  • 1990present: Women Physicians’ Committee, Missouri ACP
  • 1989 – present: Assistant Medical Director, Southwest Missouri Regional Arthritis Center
  1. Winkler, A. and D. Wilson: Thyroid acropachy: case report and review of the literature. 1985. Missouri Med 82:756-780.
  2. Winkler A., Finan, M., Pressly T. and R. Roberts: CMV retinitis in rheumatologic disease. 1987. Arthritis and Rheum 30:106-108.
  3. Pressly, T., Scott W., Ide, C., Winkler, A. and G. Reams:  Ocular complications of Tangier’s disease. 1987. Amer J Med 83:991-994.
  4. Smith, H.L., Pressly, T., Watts, C., Winkler, A. and J. Bryan: Neurosarcoid presenting as ataxia with CT and MRI findings: case report and discussion. 1987. Clin Neuroscience 1:10-11.
  5. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing a unique subset of snRNP complexes. 1988 J. Immunol 140:69-77.
  6. Winkler, A., Jackson, R., Kay, D., Mitchell, E., Carmiagnini, S. and G. Sharp: Successful treatment of SLE-associated aplastic anemia. 1988. Arthritis and Rheum 41:643-644.
  7.  Winkler, A., Pressly, T. and D. Wilson: Androgen deficient osteoporosis. 1988. Missouri Med 85:84-86.
  8. Winkler, A., Pressly, T., Alpert, M., Jackson, R., Mukerji, V. and G. Sharp: Value and limitation of calcium channel blockade in patients with pulmonary arterial hypertension associated with CREST. 1988. Angiology 39:385-389.
  9. Pressly, T., Treadwell, E., Ansbacher, L., Winkler, A. and S. Walker: Eosinophilic fascitis, porphyria cutanea tarda and granulocytopenia in a patient with inflammatory arthritis. 1989. J. Rheum.
  10. Winkler, A., Kreivi, J.P., Akusjarvi, G. and K.S. Wise: Monoclonal autoantibody recognizes higher order snRNP complex involved in splicing. Submitted.
  11. Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K., Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated 70K polypeptide. 1990. Clin Immunol Immunopath.
  12. Anderson, Frances and A Winkler: Benefits of Long-Term Fibromyalgia Treatment with Multi-disciplinary Program. J Musculoskeletal Diseases, Dec 2006.
  13. Kurland, Winkler and Coyle: Prevalence of Irritable Bowel Syndrome and Deression in Fibromyalgia. Digestive Disease and Science. 51 (3) 454-460.
  14. Anderson, Frances and A Winkler. Group Therapy in Fibromyalgia. In Press: J Musculoskeletal Diseases.
  1. Winkler, A., McKown, R. and K.S. Wise: Novel monoclonal autoantibody specificity associated with ribonucleoprotein complexes. 1986. Fed Proceedings 45:492 (Abstract 1968).
  2. Pressly, T., Winkler, A. and D. Wilson: Male osteoporosis: 2 unusual cases. 1987. Southern Medical Association, 81st Annual Scientific Assembly.
  3.  Pressly, T., Winkler, A., Alpert, M., Mukerji, V. and G. Sharp: Value and limitations of calcium channel blockade in patients with pulmonary arterial hypertension associated with the Crest syndrome. 1987. American College of Angiology , 34th Annual Meeting.
  4. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody which recognizes a unique subset of snRNP. Mol Biol Reports 12:164.
  5. Pettersson, I., Nyman, U., Winkler, A., Wise, K.S. and N. Ringertz: Colocalization studies of different sets of snRNP using monoclonal autoantibodies. 1987. EMBO Eukaryotic RNP Meeting.
  6. Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing higher order snRNP complexes. 1987. Arthritis Foundation Fellows Conference.
  7. Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K., Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated 70K polypeptide. 1990. Arthritis Rheum 32:S26.
  1. “A Randomized, Double-Blind, Parallel Group, International Study To Evaluate The Safety And Efficacy Of Ocrelizumab Compared To Placebo In Patients With Active Rheumatoid Arthritis Who Have An Inadequate Response To At Least One AntiTNF- Therapy.”  Roche & Genentech, Principal Investigator.
  2. “A Phase 2, Randomized, Double-Blind, Placebo controlled, Parallel-Group Study of CP195543 and Celecoxib Dual Therapy in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are Inadequately Controlled on Methotrexate”, Pfizer, Principal Investigator
  3. “A Randomized, Double Blind, Parallel-group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease comparing Celecoxib with Naproxen and Ibupofen”, Pfizer, Principal Investigator
  4. “Long-term extension study of safety during treatment with tocilizumab (MRA) in patients completing treatment in MRA core studies”, Hoffman-La Roche, Ltd, Principal Investigator
  5.  “A randomized, double-blind, placebo-controlled, parallel group study of the safety and reduction of signs and symptoms during treatment with MRA versus placebo, in combination with traditional DMARD therapy in patients with moderate to severe active rheumatoid arthritis and an inadequate response to current DMARD therapy”, Hoffmann-La Roche Ltd, Principal Investigator
  6. “A 39-Week, Open-Label, Extension, A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator”, Novartis Pharmaceuticals, Principal Investigator
  7. “A Multi-Center Open-Label Study to Assess the Durability and Safety of the Prevention of Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies, Principal Investigator
  8. “A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (celecoxib) vs. Placebo in the Treatment of Subjects with Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen”, Pfizer, Principal Investigator
  9. “A Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Assess Prevention of Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies, Inc., Principal Investigator
  10. “A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regiments of Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee Osteoarthritis, using Celecoxib (200 mg od) as a Comparator”,   Novartis Pharmaceuticals Corporation, Principal Investigator
  11. “A Phase III, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects with Gout”, TAP Pharmaceuticals, Principal Investigator
  12. ” Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group study assessing the efficacy of intravenous zoledornic acid in preventing subsequent osteoporotic fractures after a hip fracture”, Novartis Pharmaceuticals Corporation, Subinvestigator
  13. “An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women with Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001”, NPS Allelix, Subinvestigator
  14. “Raloxifene Alendronate Comparison In Postmenopausal Women With Osteoporosis”, Eli Lilly, Subinvestigator
  15. “A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Combination Treatment with Anakinra (IL-1ra) and PEGylated Recombinant Methionyl Human Soluble Tumor Necrosis Factor Receptor Type I (PEGsTNF-RI) in Subjects with Rheumatoid Arthritis Receiving Methotrexate”, Amgen, Inc., Principal Investigator
  16. “A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density in Postmenopausal Women with Osteoporosis. (EFFECT Study-Efficacy of Fosamax vs. Evista Comparison Trial)”, Merck & Co., Inc., Subinvestigator
  17. “An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial with a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women with Postmenopausal Osteoporosis”, NPS Allelix, Subinvestigator
  18. “A Twelve-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of Oral Alendronate Sodium (70 mg Once Weekly) in Patients with Osteoporosis”, Merck & Co., Subinvestigator
  19. “A Randomized, Placebo-Controlled, Parallel Group, Double Blind Study to Evaluate the Safety and Efficacy of Rofecoxib and Celecoxib in Patients with Osteoarthritis of the Knee or Hip”, Merck & Co., Inc., Principal Investigator
  20. “A Randomized, Double Blind, Multi-Center Study to Evaluate the Tolerability and Effectiveness of Rofecoxib (VIOXX®) 25mg q.d. Vs. Naproxen 500 mg b.i.d. in Patients with Osteoarthritis” Merck & Co., Inc., Principal Investigator

Rheumatology Articles

Rheumatology articles covering symptoms, diagnosis, staging, treatment, prognosis, and follow-up.